411 related articles for article (PubMed ID: 30849964)
1. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
2. The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden.
Wood R; Taylor-Stokes G; Smith F; Chaib C
Qual Life Res; 2019 Jul; 28(7):1849-1861. PubMed ID: 30825160
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
4. The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers.
Wood R; Taylor-Stokes G; Lees M
Support Care Cancer; 2019 May; 27(5):1709-1719. PubMed ID: 30121787
[TBL] [Abstract][Full Text] [Related]
5. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.
Yang Y; Xia Y; Su C; Chen J; Long E; Zhang H; Gan Y; Yan F; Chen Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4205-4214. PubMed ID: 36056953
[TBL] [Abstract][Full Text] [Related]
6. The direct and indirect financial costs of informal cancer care: A scoping review.
Coumoundouros C; Ould Brahim L; Lambert SD; McCusker J
Health Soc Care Community; 2019 Sep; 27(5):e622-e636. PubMed ID: 31293013
[TBL] [Abstract][Full Text] [Related]
7. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
Gridelli C; Ferrara C; Guerriero C; Palazzo S; Grasso G; Pavese I; Satta F; Bajetta E; Cortinovis D; Barbieri F; Gebbia V; Grossi F; Novello S; Baldini E; Gasparini G; Latino W; Durante E; Giustini L; Negrini C
J Thorac Oncol; 2007 Jun; 2(6):475-80. PubMed ID: 17545841
[TBL] [Abstract][Full Text] [Related]
8. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D; O'Day K; Hertel N; Penrod JR; Manley Daumont M; Lees M
Popul Health Metr; 2018 Nov; 16(1):17. PubMed ID: 30477516
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of family caregiving for elderly population in southern Ghana: the case of a peri-urban district.
Nortey ST; Aryeetey GC; Aikins M; Amendah D; Nonvignon J
Int J Equity Health; 2017 Jan; 16(1):16. PubMed ID: 28088236
[TBL] [Abstract][Full Text] [Related]
11. The social cost of chronic kidney disease in Italy.
Turchetti G; Bellelli S; Amato M; Bianchi S; Conti P; Cupisti A; Panichi V; Rosati A; Pizzarelli F;
Eur J Health Econ; 2017 Sep; 18(7):847-858. PubMed ID: 27699568
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses.
Gladman M; Dharamshi C; Zinman L
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):426-32. PubMed ID: 25025935
[TBL] [Abstract][Full Text] [Related]
14. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; Martínez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
[TBL] [Abstract][Full Text] [Related]
16. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
17. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of Huntington disease in Europe and the USA: Results from the Huntington's Disease Burden of Illness study.
Rodríguez-Santana I; Mestre T; Squitieri F; Willock R; Arnesen A; Clarke A; D'Alessio B; Fisher A; Fuller R; Hamilton JL; Hubberstey H; Stanley C; Vetter L; Winkelmann M; Doherty M; Wu Y; Finnegan A; Frank S
Eur J Neurol; 2023 Apr; 30(4):1109-1117. PubMed ID: 36421029
[TBL] [Abstract][Full Text] [Related]
19. Impact of Lung Cancer on Health-Related Quality of Life, Financial Toxicity, and Household Economics in Patients From the Public and the Private Healthcare Sector in Argentina.
Augustovski F; Tsou F; González L; Martín C; Vigo S; Gabay C; Alcaraz A; Argento F
Value Health Reg Issues; 2024 May; 41():94-99. PubMed ID: 38290167
[TBL] [Abstract][Full Text] [Related]
20. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
